RCKT Rocket Pharmaceuticals Inc
Company Analysis
Latest News
🔴 Rocket Pharmaceuticals is trading 5.9% down today amid a reported 2.01% biotech-sector decline
Rocket Pharmaceuticals is trading at $2.33 (-5.85%) during the October 13 session; a reported 2.01% biotech-sector decline may be contributing, but does not...
🟢 Rocket Pharmaceuticals is trading 5% up today after Goldman Sachs upgraded it to Neutral
Rocket Pharmaceuticals is trading at $2.67, up 5.13%, after Goldman Sachs upgraded its rating from Sell to Neutral and raised its price target from $3 to $4,...
Goldman Sachs Lifts Rocket Pharmaceuticals to Neutral, but Can a $2.79 Gene Therapy Stock Survive Until Its 2028 Moment of Truth?
Shares of Rocket Pharmaceuticals surged 10.1% to $2.79 on October 8 after Goldman Sachs upgraded the stock from Sell to Neutral and raised its price target...
🟢 Rocket Pharmaceuticals is trading 10% up in pre-market after Goldman Sachs upgraded rating to Neutral
Rocket Pharmaceuticals is trading 10.06% higher at $2.79 after Goldman Sachs upgraded its rating from Sell to Neutral and raised its price target from $3 to...
🟢 Rocket Pharmaceuticals is trading 6% up in pre-market after Goldman Sachs upgrade
Rocket Pharmaceuticals is trading 6.11% up in pre-market at $2.69 on October 8, after Goldman Sachs upgraded it from Sell to Neutral and raised its target from...
Rocket Pharma Reports Durable Heart-Mass Reductions With Danon Gene Therapy
Rocket Pharmaceuticals reported positive long-term follow-up data for RP-A501, its gene therapy for Danon disease, a rare genetic heart disorder. The results...
🟢 Rocket Pharmaceuticals is trading 5% up
Rocket Pharmaceuticals is trading at $2.62, up +5.44%, with no reported catalyst established as the cause of the gain. - The October 6 announcement of up to...
Rocket Pharmaceuticals Secures up to $150M in Senior Secured Term Loan Financing
Rocket Pharmaceuticals has entered into a Loan and Security Agreement with Hercules Capital, Inc., providing access to up to $150.0 million in senior secured...
🔴 Rocket Pharmaceuticals is trading 5% down today after announcing a $100 million underwritten stock offering
Rocket Pharmaceuticals is trading 5.17% lower at $2.48 after announcing a $100 million underwritten public stock offering. - The underwriters have a 30-day...
🟢 Rocket Pharmaceuticals is trading 5% up today without a clear company-specific catalyst
Rocket Pharmaceuticals is trading 5.21% up now at $2.73, with no clear company-specific announcement or catalyst identified for September 30, 2026. - Its...
🟢 Rocket Pharmaceuticals is trading 6.4% up in pre-market with no clear catalyst identified
Rocket Pharmaceuticals is trading 6.4% up in pre-market at $2.76, versus the September 29 close of $2.59. - No company announcement or other clearly linked...
🔴 Rocket Pharmaceuticals is trading 10% down today amid broad biotech and growth-stock pressure
On September 24, 2026, Rocket Pharmaceuticals is trading at $2.71, down 10%, amid continued pressure across biotechnology and growth stocks. - The Nasdaq is...
🔴 Rocket Pharmaceuticals is trading 6% down today amid declines in XBI and Nasdaq
Rocket Pharmaceuticals is trading at $2.84 (-5.96%) as biotechnology and risk assets weaken broadly. - XBI is down 2.04%, while the Nasdaq is down 0.80%,...
🔴 Rocket Pharmaceuticals is trading 10% down today amid broad biotech and risk-asset weakness
Rocket Pharmaceuticals is trading 10% down at $3.02 amid broad weakness across biotechnology and risk assets. - The XBI biotech ETF is down 2.04%; major U.S....
🔴 Rocket Pharmaceuticals is trading 5% down today as immediate cause remains uncertain
Rocket Pharmaceuticals is trading 5.07% down at $3.18, with no clear company-specific catalyst identified for the September 23, 2026 decline. - Recent...
🟢 Rocket Pharmaceuticals is trading 5% up today after FDA confirms continued RP-A501 trial enrollment
Rocket Pharmaceuticals is trading 5.03% up now at $3.65 after the FDA confirmed continued enrollment and dosing in its pivotal RP-A501 Phase 2 Danon disease...
🟢 Rocket Pharmaceuticals is trading 5.8% up in pre-market after FDA alignment on Danon disease trial
Rocket Pharmaceuticals is trading 5.8% up now at $3.61 after announcing FDA alignment on September 15, 2026, supporting continued enrollment and dosing in its...
🔴 Rocket Pharmaceuticals is trading 5.5% down today as biotech falls 2.11%
Rocket Pharmaceuticals is trading 5.5% down at $3.24 now, with the decline appearing driven mainly by broader risk-off conditions. - FDA alignment announced...
Rocket Pharma Secures FDA Alignment on Pivotal Phase 2 Trial for RP-A501
Rocket Pharmaceuticals announced it has reached an agreement with the U.S. Food and Drug Administration (FDA) on the key design elements for its global pivotal...
🔴 Rocket Pharmaceuticals is trading 5% down today
Rocket Pharmaceuticals is trading 5.03% down at $3.31, extending its decline from $3.48 on September 10, 2026, with no clear new company-specific negative...